1. Fitzpatrick, T.B. and M.A. Pathak, Historical aspects of methoxsalen and other furocoumarins. J Invest Dermatol, 1959. 32(2, Part 2): p. 229-31.
2. Daniell, M.D. and J.S. Hill, A history of photodynamic therapy. Aust N Z J Surg, 1991. 61(5): p. 340-8.
3. Ackroyd, R., et al., The history of photodetection and photodynamic therapy. Photochem Photobiol, 2001. 74(5): p. 656-69.
4. Roelandts, R., The history of phototherapy: something new under the sun? J Am Acad Dermatol, 2002. 46(6): p. 926-30.
5. Roelandts, R., A new light on Niels Finsen, a century after his Nobel Prize.
Photodermatol Photoimmunol Photomed, 2005. 21(3): p. 115-7.
6. Niels Ryberg Finsen The Nobel Prize in Physiology or Medicine 1903 Physiology or Medicine, Elsevier Publishing Company, Amsterdam 1967 [cited; 1901-1921]. Available from:
http://nobelprize.org/nobel_prizes/medicine/laureates/1903/finsen-bio.html.
7. Dolmans, D.E., D. Fukumura, and R.K. Jain, Photodynamic therapy for cancer. Nat Rev Cancer, 2003. 3(5): p. 380-7.
8. Kelly, J.F., Haematoporphyrins in the diagnosis and treatment of carcinoma of the bladder. Proc R Soc Med, 1975. 68(8): p. 527-8.
9. Kelly, J.F. and M.E. Snell, Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol, 1976. 115(2):
p. 150-1.
10. Dougherty, T.J., et al., Photoradiation therapy for the treatment of malignant tumors. Cancer Res, 1978. 38(8): p. 2628-35.
11. McCaughan, J.S., Jr., et al., Palliation of esophageal malignancy with photoradiation therapy. Cancer, 1984. 54(12): p. 2905-10.
12. Balchum, O.J., D.R. Doiron, and G.C. Huth, Photoradiation therapy of endobronchial lung cancers employing the photodynamic action of hematoporphyrin derivative. Lasers Surg Med, 1984. 4(1): p. 13-30.
13. Hayata, Y., et al., Photodynamic therapy with hematoporphyrin derivative in cancer of the upper gastrointestinal tract. Semin Surg Oncol, 1985. 1(1):
p. 1-11.
14. Schwartz, S.K., K. Abolon, and V. H, Some relationships of porphyrins, X-rays and tumors. Univ. Minn. Med. Bull, 1955. 27: p. 7-8.
15. Kinsey, J.H., et al., Photodynamic effect of hematoporphyrin derivative as a function of optical spectrum and incident energy density. Cancer Res, 1981.
41(12 Pt 1): p. 5020-6.
16. Lipson, R.L. and E.J. Baldes, The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol, 1960. 82: p. 508-16.
17. Diamond, I., et al., Photodynamic therapy of malignant tumours. Lancet, 1972. 2(7788): p. 1175-7.
18. Gomer CJ, R.N., Ferrario A, Wong S., Properties and applications of photodynamic therapy. Radiate Res, 1989. 120: p. 1-18.
19. Fukuda, H., A. Casas, and A. Batlle, Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell Biol, 2005. 37(2): p. 272-6.
20. Lang, K., et al., Aminolevulinic acid (Levulan) in photodynamic therapy of actinic keratoses. Skin Therapy Lett, 2001. 6(10): p. 1-2, 5.
21. Bottomley, S.S. and U. Muller-Eberhard, Pathophysiology of heme synthesis. Semin Hematol, 1988. 25(4): p. 282-302.
22. P.Hinnen, F.W.M.D.R., M.L.F. van Velthuysen, A. Edixhoven, R. van Hillegersberg, H.W. Tilnaus, Biochemical basis of 5-aminolevulinic
acid-induced protoporphyrin IX accumulation: a study in patients with (pre) malignant lesions of the esophagus. Br. J. Cancer, 1998. 78: p. 679-682.
23. M. Kondo, N.H., T. Takaoka, M. Kajiwara, Heme-biosynthesis enzyme activities and porphyrin accumulation in normal and hepatoma cell lines of rate. Cell Biol. Toxicol, 1993. 9: p. 95-105.
24. Senior, K., Photodynamic therapy for bladder cancer. Lancet Oncol, 2005.
6(8): p. 546.
25. Seidl, J., et al., Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic
acid-induced protoporphyrin IX as sensitizer. Int J Cancer, 2001. 92(5): p.
671-7.
26. Colby, T.V., Malignancies in the lung and pleura mimicking benign processes. Semin Diagn Pathol, 1995. 12(1): p. 30-44.
27. Adebonojo, S.A., et al., Impact of revised stage classification of lung cancer on survival: a military experience. Chest, 1999. 115(6): p. 1507-13.
28. Baumann, M., et al., Dose and fractionation concepts in the primary
radiotherapy of non-small cell lung cancer. Lung Cancer, 2001. 33 Suppl 1:
p. S35-45.
29. Okunaka, T., et al., Photodynamic therapy for multiple primary bronchogenic carcinoma. Cancer, 1991. 68(2): p. 253-8.
30. Bartal, M., Health effects of tobacco use and exposure. Monaldi Arch Chest Dis, 2001. 56(6): p. 545-54.
31. Mountain, C.F., A new international staging system for lung cancer. Chest, 1986. 89(4 Suppl): p. 225S-233S.
32. Kondo, K. and Y. Monden, [Therapy for multiple primary lung cancers].
Kyobu Geka, 2002. 55(1): p. 4-9.
33. Konaka, C., et al., [Photodynamic therapy for multiple primary lung cancer].
Gan To Kagaku Ryoho, 1996. 23(1): p. 31-5.
34. Chu, Y.W., et al., Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol, 1997.
17(3): p. 353-60.
35. Baldrick, P., Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol, 2000. 32(2): p. 210-8.
36. Scott, A.W., Non-medicinal ingredients. Drug Saf, 1990. 5 Suppl 1: p.
95-100.
37. Schlocker, W., S. Gschliesser, and A. Bernkop-Schnurch, Evaluation of the potential of air jet milling of solid protein-poly(acrylate) complexes for microparticle preparation. Eur J Pharm Biopharm, 2006. 62(3): p. 260-6.
38. Bernkop-Schnurch, A., C. Paikl, and C. Valenta, Novel bioadhesive
chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm Res, 1997. 14(7): p. 917-22.
39. Luessen, H.L., et al., Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res, 1995. 12(9): p. 1293-8.
40. Takeuchi, H., et al., Mucoadhesive properties of carbopol or
chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release, 2003. 86(2-3): p. 235-42.
41. Takeuchi, H., H. Yamamoto, and Y. Kawashima, Mucoadhesive
nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev, 2001. 47(1): p. 39-54.
42. Lee, J.W., J.H. Park, and J.R. Robinson, Bioadhesive-based dosage forms:
the next generation. J Pharm Sci, 2000. 89(7): p. 850-66.
43. Smart, J.D., Recent developments in the use of bioadhesive systems for delivery of drugs to the oral cavity. Crit Rev Ther Drug Carrier Syst, 2004.
21(4): p. 319-44.
44. Surapaneni, M.S., S.K. Das, and N.G. Das, Effect of excipient and processing variables on adhesive properties and release profile of pentoxifylline from mucoadhesive tablets. Drug Dev Ind Pharm, 2006.
32(3): p. 377-87.
45. Rege, B.D., et al., Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci, 2001. 90(11): p. 1776-86.
46. Pifferi, G., P. Santoro, and M. Pedrani, Quality and functionality of excipients. Farmaco, 1999. 54(1-2): p. 1-14.
47. Takeshi Nakanishi, Fusao Kaiho, and M. Hayashi, Use of sodium salt of Carbopol 934P in oral peptide delivery. International Journal of
Pharmaceutics 1998. 171(2): p. 177-183.
48. Ozeki, T., H. Yuasa, and Y. Kanaya, Controlled release from solid dispersion composed of poly(ethylene oxide)-Carbopol interpolymer
complex with various cross-linking degrees of Carbopol. J Control Release, 2000. 63(3): p. 287-95.
49. Rud E, et al., 5-Aminolevulinic acid, but not 5-Aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters.
Photochem Photobiol 2000. 73: p. 164-169.
50. F, D., et al., Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest, 1998. 101: p. 2761-2767.
51. Novotny A, et al., Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem 2000. 75: p. 321-328.
52. Whitaker C, et al., Photosensitization of pancreatic tumour cells by 5-aminolevulinic acid esters. Anti-Cancer Drugs Design, 2000. 15: p.
161-170.
53. Palacı´n M, et al., Molecular biology of mammalian plasma membrane amino acids transporters. . Physiological Reviews 1998. 78: p. 969-1054.
54. Hua, Z., et al., Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo.
Cancer Res, 1995. 55(8): p. 1723-31.
55. Navone, N.M., et al., Heme biosynthesis in human breast cancer--mimetic
"in vitro" studies and some heme enzymic activity levels. Int J Biochem, 1990. 22(12): p. 1407-11.
56. Navone, N.M., et al., Mouse mammary carcinoma porphobilinogenase and hydroxymethylbilane synthetase. Comp Biochem Physiol B, 1991. 98(1): p.
67-71.
57. Van Hillegersberg, R., et al., Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology, 1992. 103(2): p. 647-51.
58. Jones, B.U., et al., Photodynamic therapy for patients with advanced non-small-cell carcinoma of the lung. Clin Lung Cancer, 2001. 3(1): p.
37-41; discussion 42.
59. Lisnjak, I.O., et al., Effect of photodynamic therapy on tumor angiogenesis and metastasis in mice bearing Lewis lung carcinoma. Exp Oncol, 2005.
27(4): p. 333-5.
60. Parisi A, W.J., Kimlin MG, Turnbull D, Lester R., Comparison between seasons of the ultraviolet environment in the shade of tree in Australia.
Photodermatol Photoimmunol Photomed, 2001. 17: p. 55-59.
61. Glanz K, S.M., Wechsler H., Guidelines for school programs to prevent skin cancer. MMWR Morb Mortal Wkly Rep, 2002. 51: p. 1-18.
62. Ichihashi M, U.M., Budiyanto A, Bito T, Oka M, Fukunaga M, Tsuru K, Horikawa T, UV-induced skin damage. Toxicology, 2003. 189: p. 21-39.
63. Nadim A. Shaath , e.N.Y.M.D., Sunscreen: Regulations and Commercial Development. 3rd edition ed. 2005.
64. 蔡禎輝、劉銘龍、柳中明, 抗紫外線產品測試及檢測標準比較分析, in
65. Applegate, L.A., Ley, R.D., Alcalay, j., Kripke, M.L., Indentification of the molecular target for the suppression of contact hypersensitivy by UV
radiation. J. Exp. Med., 1989. 170: p. 1117-1131.
66. Aszterbaum, M., Rothman, A., Johnson, R.L., Fisher, M., Xie, and B. J., J.M., Zhang, X., Scott, M.P., Epstein, E.H., Jr., Identification of mutations in the human patched gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol, 1998. 110: p.
885-888.
67. Aragane, Y., Kulms, D., Metze, D., Wilkes, G., Poppelmann, B., Luger, T.A., Schwarz, T., Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J. Cell Biol, 1998.
140: p. 171-182.
68. Urbach F., G.P.U., Sun Protection in Man. first ed. The negative effects of solar radiation: a clinical overview. 2001, NY. 39-67.
69. Wang Xiao-uoung, B.Z.-g., UVB-irradiated human keratinocytes and interlukin-1a indirectly increase MAP kinase/AP-1 activation and MMP-1 production in UVA-irradiated dermal fibroblasts. Chinese Medical Journal, 2006. 119: p. 827-831.
70. Hersey P, H.G., Hasic E, Edwards A, Alteration of T-cell subset and induction of suppressor T-cell activity in normal sujects after exposure to sunlight. J Immunol, 1983. 131: p. 171-174.
71. Shaath, N.A., Sunscreens. Regulations and Commercial Development Third Edition. Vol. 28. 2005, NY: Taylor & Francis Group.
72. http://www.cibasc.com.
73. L., M., Egyptian luxuries: fragrance, aromatherapy, and cosmetics in pharaonic times. 1999.
74. Bissonnette, R., Update on sunscreens. Skin Therapy Letter, 1997. 2: p. 3-6.
75. G., P., perfluoropolyethers in sunscreens. 1988. 143: p. 42.
76. JF., N., Human safety and efficancy of ultraviolet filters and sunscreen products. Dermatol Clin, 2006(24): p. 35-51.
77. Naylor M, B.A., Smith DW, Cameron GS, Hubbard D, Neldner KH, High sun protection factor sunscreens in the suppression of actinic neoplasia.
Arch Dermatol, 1995. 131: p. 170-175.
78. Green A, W.G., Neal R, Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet, 1999. 354: p. 723-729.
79. Maier T, K.H., Sunscreens-which and what for? Skin Pharmacol Physiol, 2005. 18(6): p. 253-262.
80. Autier, P., Sunscreen use and duration of sun exposure: A double-blind, randomized trial. Journal of the National Cancer Institute, 1999. 91: p.
1304-1309.
81. Amblard, P., Is it dangerous to use sunscreen agents? Ann Dermatol Venereol, 1994. 121: p. 875-879.
82. Garland, C.F., Rising trends in melanoma: A hypothesis concerning sunscreens. Ann Epidemiol, 1993. 3: p. 103-110.
83. Nohynek, G.J., Benefit and Risk of Organic Ultraviolet Filters. Regulatory Toxicology and Pharmacology, 2001. 33: p. 285-299.
84. Autier, P., Influence of sun exposure during childhood and during adulthood on melanoma risk. Int. J. Cancer, 1998. 77: p. 533-537.
85. Hayden, C.G.J., A profile of the skin penetration of a common sunscreening agent: Oxybenzone. Cut. Penetration, 1997. 5B: p. 236-238.
86. Jiang, R., Skin penetration from sunscreens from commercial products.
Perspect. Cut. Penetration, 1997. 5B: p. 239-241.
87. Garland, C.F., Could sunscreens increase melanoma risk? Am. J. Pub.
Health, 1992. 82: p. 614-615.
88. Westerdahl, J., Sunscreen use and malignant melanoma. Int. J. Cancer, 2000.
87: p. 145-150.
89. Boehm, F., Hazards of sunscreens-Cytotoxic properties of micronized titandioxide. In Biological Effects of Light, 1995: p. 446-451.
90. Butt, S.T., Toxicity and phototoxicity of chemical sun filters. Radiat. Prot.
Dosim, 2000. 91: p. 283-286.
91. MK., R., Population differences in actue skin irritation responses. Race, sex, age, sensitive skin and repeat subject comparisions. Contact Dermatitis, 2002. 46(2): p. 86-93.
92. Shaath NA, e., Sunscreens: Regulations and Commercial Development.
93. R.C. Lindenschmidt, F.B.A., M. Dorta, L. Bansil, Global cosmetic regulatory harmonization. Toxicology, 2001. 160: p. 237-241.
94. Federal Register. 27666. 1999.
95. M., F., Self-reported skin type of Japanese. J Jpn Cosmet Soc, 1991. 15: p.
103-105.
96. T., Y., The survery about female attitude against their skin and the character of their skin- the international comparison of surveys conducted in Japan, US, Europe and Asia. J Jpn Cosmet Soc Cutan Health, 2003. 50: p. 68-74.
97. JCIA, Japan Cosmetic Industry Association Standard Sun Protection Factor Test Method. 1991.
98. 行政院衛生署藥物食品檢驗局. http://www.nlfd.gov.tw.
99. Kunz, P.Y. and K. Fent, Estrogenic activity of UV filter mixtures. Toxicol Appl Pharmacol, 2006. 217(1): p. 86-99.